Photo of Dawn Flitcraft

Ms. Flitcraft joined WCG in 2016 as the chief M&A integration officer, collaborating with various stakeholders to ensure that the necessary people, processes, and technology are in place to achieve success post transaction. Since 2018, Ms. Flitcraft has led the ethical review division. She is responsible for the efficient and compliant operation of all IRBs.

Ms. Flitcraft has more than 13 years of clinical trial experience, leading global project management and operational teams at various companies in the drug and device development industries.

Ms. Flitcraft earned a BS in nuclear medicine and biology from Cedar Crest College in Allentown PA; she also holds a certification in M&A integration. Most recently, Ms. Flitcraft was named to the 2020 PharmaVOICE 100 list of honorees.